ALLERGIC MANIFESTATIONS OF PRIMARY IMMUNODEFICIENCY DISEASES AND ITS TREATMENT APPROACHES
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i11.29059Keywords:
Allergic manifestations, Primary immunodeficiencies, Treatment approachesAbstract
Allergic manifestations are one of the clinical signs of primary immunodeficiency diseases (PID). In this review, the common allergic manifestations of PID are summarized, and their main differential characteristics and treatment approaches are outlined. Allergic manifestations occur more often in patients with combined immunodeficiencies with or without associated or syndromic features. In patients with PID they usually are present in the 1st year of life, may be among the first symptoms of PID, and are commonly manifested by eczema and increased immunoglobulin (Ig)-G levels. Often the skin barrier function is not impaired in patients with eczema and PID, although some diseases (such as Comel-Netherton syndrome) do affect skin barrier function. There is usually no correlation between IgE levels and the severity of allergic skin manifestations. Allergic-like manifestations in PID patients include urticaria-like rash and angioedema. Urticaria-like rash is associated with autoinflammatory disorders, which are commonly accompanied by fever, and caused by a neutrophilic infiltrate in the dermis. Angioedema in hereditary angioedema patients is caused by high bradykinin production. Early differentiation of allergic manifestations in PID from atopic dermatitis and other atopic conditions is very difficult; however, it is very important because it influences on treatment methods. A multidisciplinary approach to the management of PID patients, with the involvement of immunologists, allergists, and formulation of appropriate treatment improve the prognosis and quality of life of the PID patients.
Downloads
References
Bousfiha AA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova JL, et al. Primary immunodeficiency diseases worldwide: More common than generally thought. J Clin Immunol 2013;33:1-7.
Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: An update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2014;5:162.
Modell V, Orange JS, Quinn J, Modell F. Global report on primary immunodeficiencies: 2018 update from the Jeffrey Modell centers network on disease classification, regional trends, treatment modalities, and physician reported outcomes. Immunol Res 2018; Doi: 10.1007/ s12026-018-8996-5.
Kumar Y, Bhatia A. Immunopathogenesis of allergic disorders: Current concepts. Expert Rev Clin Immunol 2013;9:211-26.
Fedortsiv O, Brozek GM, Luchyshyn N, Kubey I, Lawson JA, Rennie DC, et al. Prevalence of childhood asthma, rhinitis, and eczema in the Ternopil region of Ukraine – results of BUPAS study. Adv Med Sci 2012;57:282-9.
Boyarchuk O, Lewandowicz-Uszynska A, Kinash M, Haliyash N, Sahal I, Kovalchuk T. Physicians’ awareness concerning primary immunodeficiencies in Ternopil region, Ukraine. Pediatr Pol 2018;93:221-8.
Lehman H. Skin manifestations of primary immune deficiency. Clin Rev Allergy Immunol 2014;46:112-9.
Zhang Q, Davis JC, Dove CG, Su HC. Genetic, clinical, and laboratory markers for DOCK8 immunodeficiency syndrome. Dis Markers 2010;29:131-9.
Chu EY, Freeman AF, Jing H, Cowen EW, Davis J, Su HC, et al. Cutaneous manifestations of DOCK8 deficiency syndrome. Arch Dermatol 2012;148:79-84.
Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med 2009;361:2046-55.
Su HC. Dedicator of cytokinesis 8 (DOCK8) deficiency. Curr Opin Allergy Clin Immunol 2010;10:515-20.
Purcell C, Cant A, Irvine AD. DOCK8 primary immunodeficiency syndrome. Lancet 2015;386:982.
Biggs CM, Keles S, Chatila TA. DOCK8 deficiency: Insights into pathophysiology, clinical features and management. Clin Immunol 2017;181:75-82.
Dimitrova D, Freeman AF. Current status of dedicator of cytokinesis-associated immunodeficiency: DOCK8 and DOCK2. Dermatol Clin 2017;35:11-9.
Engelhardt KR, Gertz ME, Keles S, Schäffer AA, Sigmund EC, Glocker C, et al. The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol 2015;136:402-12.
Zhang ZY, Zhao XD, Jiang LP, Liu EM, Cui YX, Wang M, et al. Clinical characteristics and molecular analysis of three Chinese children with Omenn syndrome. Pediatr Allergy Immunol 2011;22:482-7.
Wang YQ, Cui YX, Feng J. Clinical phenotype and gene diagnostic analysis of Omenn syndrome. Zhonghua Er Ke Za Zhi 2013;51:64-8.
Liao CY, Yu HW, Cheng CN, Chen JS, Lin CW, Chen PC, et al. A novel pathogenic mutation on interleukin-7 receptor leading to severe combined immunodeficiency identified with newborn screening and whole exome sequencing. J Microbiol Immunol Infect 2018;2018:S1182-684.
Gruber TA, Shah AJ, Hernandez M, Crooks GM, Abdel-Azim H, Gupta S, et al. Clinical and genetic heterogeneity in Omenn syndrome and severe combined immune deficiency. Pediatr Transplant 2009;13:244-50.
Couëdel C, Roman C, Jones A, Vezzoni P, Villa A, Cortes P, et al. Analysis of mutations from SCID and Omenn syndrome patients reveals the central role of the rag2 PHD domain in regulating V(D)J recombination. J Clin Invest 2010;120:1337-44.
Zafar R, Ver Heul A, Beigelman A, Bednarski JJ, Bayliss SJ, Dehner LP, et al. Omenn syndrome presenting with striking erythroderma and extreme lymphocytosis in a newborn. Pediatr Dermatol 2017;34:e37-9.
Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr 1994;125:876-85.
Bastida JM, Del Rey M, Revilla N, Benito R, Perez-Andrés M, González B, et al. Wiskott-Aldrich syndrome in a child presenting with macrothrombocytopenia. Platelets 2017;28:417-20.
Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2006;117:725-38.
Lanzi G, Moratto D, Vairo D, Masneri S, Delmonte O, Paganini T, et al. A novel primary human immunodeficiency due to deficiency in the WASP-interacting protein WIP. J Exp Med 2012;209:29-34.
de la Fuente MA, Sasahara Y, Calamito M, Antón IM, Elkhal A, Gallego MD, et al. WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP). Proc Natl Acad Sci U S A 2007;104:926-31.
Boos AC, Hagl B, Schlesinger A, Halm BE, Ballenberger N, Pinarci M, et al. Atopic dermatitis, STAT3- and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization pattern. Allergy 2014;69:943-53.
Mócsai G, Gáspár K, Dajnoki Z, Tóth B, Gyimesi E, BÃró T, et al. Investigation of skin barrier functions and allergic sensitization in patients with hyper-IgE syndrome. J Clin Immunol 2015;35:681-8.
Wu J, Chen J, Tian ZQ, Zhang H, Gong RL, Chen TX, et al. Clinical manifestations and genetic analysis of 17 patients with autosomal dominant hyper-IgE syndrome in Mainland China: New reports and a literature review. J Clin Immunol 2017;37:166-79.
Siegel AM, Stone KD, Cruse G, Lawrence MG, Olivera A, Jung MY, et al. Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation. J Allergy Clin Immunol 2013;132:1388-96.
Hagl B, Heinz V, Schlesinger A, Spielberger BD, Sawalle-Belohradsky J, Senn-Rauh M, et al. Key findings to expedite the diagnosis of hyper- IgE syndromes in infants and young children. Pediatr Allergy Immunol 2016;27:177-84.
Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, Tsuchiya S, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006;25:745-55.
Kilic SS, Hacimustafaoglu M, Boisson-Dupuis S, Kreins AY, Grant AV, Abel L, et al. A patient with tyrosine kinase 2 deficiency without hyper- IgE syndrome. J Pediatr 2012;160:1055-7.
Kreins AY, Ciancanelli MJ, Okada S, Kong XF, RamÃrez-Alejo N, Kilic SS, et al. Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med 2015;212:1641-62.
Bitoun E, Chavanas S, Irvine AD, Lonie L, Bodemer C, Paradisi M. Netherton syndrome: Disease expression and spectrum of SPINK5 mutations in 21 families. J Invest Dermatol 2002;118:352-61.
Stoll C, Alembik Y, Tchomakov D, Messer J, Heid E, Boehm N, et al. Severe hypernatremic dehydration in an infant with Netherton syndrome. Genet Couns 2001;12:237-43.
Wang S, Olt S, Schoefmann N, Stuetz A, Winiski A, Wolff-Winiski B, et al. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: Effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7. Exp Dermatol 2014;23:524-6.
Komatsu N, Saijoh K, Jayakumar A, Clayman GL, Tohyama M, Suga Y, et al. Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients. J Invest Dermatol 2008;128:1148-59.
Hovnanian A. Netherton syndrome: Skin inflammation and allergy by loss of protease inhibition. Cell Tissue Res 2013;351:289-300.
Hwa V. STAT5B deficiency: Impacts on human growth and immunity. Growth Horm IGF Res 2016;28:16-20.
Hwa V, Nadeau K, Wit JM, Rosenfeld RG. STAT5b deficiency: Lessons from STAT5b gene mutations. Best Pract Res Clin Endocrinol Metab 2011;25:61-75.
Klammt J, Neumann D, Gevers EF, Andrew SF, Schwartz ID, Rockstroh D, et al. Dominant-negative STAT5B mutations cause growth hormone insensitivity with short stature and mild immune dysregulation. Nat Commun 2018;9:2105.
Yel L. Selective igA deficiency. J Clin Immunol 2010;30:10-6.
Janzi M, Kull I, Sjöberg R, Wan J, Melén E, Bayat N, et al. Selective IgA deficiency in early life: Association to infections and allergic diseases during childhood. Clin Immunol 2009;133:78-85.
Edwards E, Razvi S, Cunningham-Rundles C. IgA deficiency: Clinical correlates and responses to pneumococcal vaccine. Clin Immunol 2004;111:93-7.
Aghamohammadi A, Cheraghi T, Gharagozlou M, Movahedi M, Rezaei N, Yeganeh M, et al. IgA deficiency: Correlation between clinical and immunological phenotypes. J Clin Immunol 2009;29:130-6.
Balzar S, Strand M, Nakano T, Wenzel SE. Subtle immunodeficiency in severe asthma: IgA and IgG2 correlate with lung function and symptoms. Int Arch Allergy Immunol 2006;140:96-102.
Kim WJ, Choi IS, Kim CS, Lee JH, Kang HW. Relationship between serum IgA level and allergy/asthma. Korean J Intern Med 2017;32:137-45.
Bin Dhuban K, Piccirillo CA. The immunological and genetic basis of immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Curr Opin Allergy Clin Immunol 2015;15:525-32.
Barzaghi F, Hernandez LC, Neven B, Ricci S, Kucuk ZY, Bleesing JJ, et al. Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. J Allergy Clin Immunol 2018;141:1036-49.
Gambineri E, Perroni L, Passerini L, Bianchi L, Doglioni C, Meschi F, et al. Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: Inconsistent correlation between forkhead box protein 3 expression and disease severity. J Allergy Clin Immunol 2008;122:1105-120.
Milner JD. PLAID: A Syndrome of complex patterns of disease and unique phenotypes. J Clin Immunol 2015;35:527-30.
Abajian M, MÅ‚ynek A, Maurer M. Physical urticaria. Curr Allergy Asthma Rep 2012;12:281-7.
Ombrello MJ, Remmers EF, Sun G, Freeman AF, Datta S, Torabi-Parizi P, et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med 2012;366:330-8.
Sassi A, Lazaroski S, Wu G, Haslam SM, Fliegauf M, Mellouli F, et al. Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels. J Allergy Clin Immunol 2014;133:1410-9, 1419.e1-13.
Zhang Y, Yu X, Ichikawa M, Lyons JJ, Datta S, Lamborn IT, et al. Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment. J Allergy Clin Immunol 2014;133:1400-9, 1409.e1-5.
Pichard DC, Freeman AF, Cowen EW. Primary immunodeficiency update: Part I. Syndromes associated with eczematous dermatitis. J Am Acad Dermatol 2015;73:355-64.
Abdollahpour H, Appaswamy G, Kotlarz D, Diestelhorst J, Beier R, Schäffer AA, et al. The phenotype of human STK4 deficiency. Blood 2012;119:3450-7.
Nehme NT, Schmid JP, Debeurme F, André-Schmutz I, Lim A, Nitschke P, et al. MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival. Blood 2012;119:3458-68.
Goldbach-Mansky R. Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. Curr Rheumatol Rep 2011;13:123-31.
Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001;29:301-5.
Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006;355:581-92.
Lachmann HJ, Papa R, Gerhold K, Obici L, Touitou I, Cantarini L, et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: A series of 158 cases from the euro fever/ EUROTRAPS international registry. Ann Rheum Dis 2014;73:2160-7.
Ueda N, Ida H, Washio M, Miyahara H, Tokunaga S, Tanaka F, et al. Clinical and genetic features of patients with TNFRSF1A variants in Japan: Findings of a nationwide survey. Arthritis Rheumatol 2016;68:2760-71.
Caso F, Galozzi P, Costa L, Sfriso P, Cantarini L, Punzi L, et al. Autoinflammatory granulomatous diseases: From Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and crohn’s disease. RMD Open 2015;1:e000097.
Rosé CD, Pans S, Casteels I, Anton J, Bader-Meunier B, Brissaud P, et al. Blau syndrome: Cross-sectional data from a multicentre study of clinical, radiological and functional outcomes. Rheumatology (Oxford) 2015;54:1008-16.
Wouters CH, Maes A, Foley KP, Bertin J, Rose CD. Blau syndrome, the prototypic auto-inflammatory granulomatous disease. Pediatr Rheumatol Online J 2014;12:33.
Pappalardo E, Cicardi M, Duponchel C, Carugati A, Choquet S, Agostoni A, et al. Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. J Allergy Clin Immunol 2000;106:1147-54.
Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al. Classification, diagnosis, and approach to treatment for angioedema: Consensus report from the hereditary angioedema international working group. Allergy 2014;69:602-16.
Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 2007;119:1497-503.
Boyarchuk O, Volyanska L, Dmytrash L. Clinical variability of chromosome 22q11.2 deletion syndrome. Cent Eur J Immunol 2017;42:412-7.
Appalasamy JR, Sariff A. A survey of drug-related-problems among patients treated for allergy symptoms in community pharmacies at Negeri Sembilan, Malaysia. Int J Pharm Pharm Sci 2014;6:313-6.
Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: An updated cochrane review. Br J Dermatol 2010;163:12-26.
Peacocke M, Siminovitch KA. Wiskott-Aldrich syndrome: New molecular and biochemical insights. J Am Acad Dermatol 1992;27:507-19.
Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005;94:S1-63.
Ghosh S, Schuster FR, Adams O, Babor F, Borkhardt A, Comoli P, et al. Haploidentical stem cell transplantation in DOCK8 deficiency - Successful control of pre-existing severe viremia with a TCRaß/CD19-depleted graft and antiviral treatment. Clin Immunol 2014;152:111-4.
Passerini L, Santoni de Sio FR, Porteus MH, Bacchetta R. Gene/cell therapy approaches for immune dysregulation polyendocrinopathy enteropathy X-linked syndrome. Curr Gene Ther 2014;14:422-8.
Horino S, Sasahara Y, Sato M, Niizuma H, Kumaki S, Abukawa D, et al. Selective expansion of donor-derived regulatory T cells after allogeneic bone marrow transplantation in a patient with IPEX syndrome. Pediatr Transplant 2014;18:E25-30.
Renner ED, Hartl D, Rylaarsdam S, Young ML, Monaco-Shawver L, Kleiner G, et al. Comèl-Netherton syndrome defined as primary immunodeficiency. J Allergy Clin Immunol 2009;124:536-43.
Caglayan Sozmen S, Isik S, Arikan Ayyildiz Z, Yildiz K, Cakır Y, Ozer E, et al. Cyclosporin treatment improves skin findings in Omenn syndrome. Pediatr Dermatol 2015;32:e54-7.
Abbas RS, Abdulridha MK, Shafek MA. Clinical evaluation of the potential anti-inflammatory effect of Vitamin D3 adjuvant therapy for chronic asthma in Iraqi patients. Int J Pharm Pharm Sci 2017;9:139-44.
Capo V, Castiello MC, Fontana E, Penna S, Bosticardo M, Draghici E, et al. Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation. J Allergy Clin Immunol 2018;142:928-41.
Ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 2015;74:1636-44.
Gattorno M, Obici L, Cattalini M, Tormey V, Abrams K, Davis N, et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): An open-label, phase II study. Ann Rheum Dis 2017;76:173-8.
Quillinan N, Mannion G, Mohammad A, Coughlan R, Dickie LJ, McDermott MF, et al. Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome. Ann Rheum Dis 2011;70:1692-3.
Rammel J, Rosillo P, Vogel T, de Guzman M. Treatment of blau syndrome with biologic therapy: A single center case series of seven patients over two decades. Arthritis Rheum 2017;69 Suppl 4:80.
Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010;363:513-22.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
